Endocrine Pharmacology

The clinical manipulation of the endocrine system has its roots in observations dating back centuries, yet the pharmacological era truly began only when scientists could isolate, characterize, and synthesize hormones. Understanding the historical trajectory of endocrine pharmacology is essential because the therapeutic strategies tested on USMLE Step 1—replacement therapy, suppression protocols, and receptor modulation—were each born from a specific clinical problem that demanded a molecular solution. The endocrine system, with its feedback loops connecting the hypothalamus, pituitary, and peripheral glands, provides an extraordinarily rich set of drug targets, and much of modern pharmacology was shaped by the race to exploit those targets.

From crude glandular extracts to recombinant proteins and small-molecule receptor modulators, endocrine pharmacology has consistently asked one central question: How can we restore, suppress, or redirect hormonal signaling to treat disease? The sections that follow dissect the drugs and mechanisms you need to master for Step 1, organized around the major hormonal axes.

Before diving into individual drug classes, it is critical to internalize the foundational principles that govern every endocrine drug interaction tested on boards. Most endocrine drugs work by either replacing a deficient hormone, blocking the synthesis or action of an excess hormone, or exploiting receptor pharmacology to achieve tissue-selective effects. The feedback architecture of the hypothalamic-pituitary-peripheral gland axis is central to understanding both desired therapeutic effects and adverse consequences such as adrenal suppression or rebound hyperthyroidism.

As depicted in the diagram, virtually every pharmacologic intervention in endocrine medicine can be mapped onto one of three tiers. At the hypothalamic level, GnRH agonists and antagonists alter gonadotropin release; at the pituitary level, dopamine agonists suppress prolactin and somatostatin analogues suppress GH; and at the peripheral gland/receptor level, enzyme inhibitors (e.g., methimazole for thyroid peroxidase, ketoconazole for adrenal steroidogenesis) and receptor modulators (e.g., SERMs, spironolactone) exert their effects. Understanding this hierarchy allows you to predict drug effects, anticipate feedback-mediated complications, and answer vignette-style Step 1 questions with confidence.

Thyroid Axis Pharmacology

The thyroid gland concentrates iodide via the sodium-iodide symporter (NIS), organifies it using thyroid peroxidase (TPO), couples iodotyrosines, and releases T₃ and T₄. Pharmacologic intervention targets each of these steps. Propylthiouracil (PTU) inhibits both TPO and peripheral 5′-deiodinase (the enzyme converting T₄ to the more potent T₃), making it preferred in thyroid storm and the first trimester of pregnancy. Methimazole inhibits TPO alone but has better compliance (once-daily dosing) and is the mainstay of long-term antithyroid therapy; however, it is teratogenic (aplasia cutis) and avoided in the first trimester. Both thionamides carry a risk of agranulocytosis, and patients must be warned to report sore throat and fever immediately.

Levothyroxine (T₄) is the standard replacement for hypothyroidism; it has a long half-life of approximately 7 days and is peripherally converted to T₃. Monitoring is via TSH levels (elevated TSH indicates under-replacement). Radioactive iodine (¹³¹I) is used for definitive ablation of the thyroid in Graves disease, exploiting the gland's avid iodine uptake to deliver targeted radiation.

Adrenal Axis Pharmacology

Glucocorticoids such as prednisone, prednisolone, dexamethasone, and hydrocortisone activate intracellular glucocorticoid receptors that translocate to the nucleus and modulate gene transcription. Their effects span anti-inflammatory, immunosuppressive, and metabolic domains. Pharmacologic dosing suppresses the HPA axis via negative feedback on CRH and ACTH; chronic use leads to adrenal atrophy, and abrupt withdrawal can precipitate acute adrenal insufficiency. Fludrocortisone has predominantly mineralocorticoid activity and is used in primary adrenal insufficiency to replace aldosterone. On the suppression side, ketoconazole (inhibits multiple CYP enzymes in steroidogenesis), metyrapone (inhibits 11β-hydroxylase), and aminoglutethimide (inhibits cholesterol desmolase/CYP11A1) reduce cortisol production and are used diagnostically or in Cushing syndrome.

Gonadal Axis Pharmacology

The HPG axis is manipulated at multiple levels. Leuprolide is a GnRH agonist that, when given continuously, downregulates GnRH receptors and ultimately suppresses FSH and LH release; this is used in prostate cancer, endometriosis, precocious puberty, and uterine fibroids. Notably, there is an initial hormonal flare (transient increase in testosterone/estrogen) before suppression occurs, which can worsen symptoms temporarily. GnRH antagonists (e.g., degarelix) avoid this flare by immediately blocking the GnRH receptor. Clomiphene is a SERM that blocks estrogen receptors in the hypothalamus, preventing negative feedback and thereby increasing GnRH pulsatility and gonadotropin release to induce ovulation. Tamoxifen antagonizes estrogen receptors in breast tissue (used in ER-positive breast cancer) but acts as a partial agonist in the uterus, increasing the risk of endometrial cancer. Raloxifene is another SERM that acts as an agonist in bone (preventing osteoporosis) and an antagonist in both breast and uterus, thus lacking the endometrial cancer risk of tamoxifen. Aromatase inhibitors (anastrozole, letrozole, exemestane) block the conversion of androgens to estrogens in peripheral tissues and are used in postmenopausal ER-positive breast cancer.

Step 1 questions in endocrine pharmacology typically present as clinical vignettes requiring you to identify a drug mechanism, predict a side effect, or choose the most appropriate agent. The following worked example demonstrates the systematic approach to dissecting such a question.

One of the most efficient ways to solidify endocrine pharmacology knowledge is to compare drugs that act on the same axis but differ in their specifics. The following tables address comparisons that appear repeatedly on Step 1 and help you distinguish drugs that students frequently confuse.

While Step 1 focuses on mechanisms, pharmacokinetics, and side effect profiles, the concepts covered here form the foundation for clinical decision-making tested on Step 2 CK and Step 3. Understanding how these drugs integrate into treatment algorithms, when to switch agents, and how to manage the complications of long-term therapy is the natural extension of Step 1 pharmacology.

Several emerging areas that are beginning to appear on updated Step 1 content include SGLT2 inhibitor cardio-renal benefits (empagliflozin, dapagliflozin—now first-line in heart failure with reduced EF regardless of diabetes status), GLP-1 receptor agonist weight loss effects (semaglutide), and the growing role of checkpoint inhibitor-induced endocrinopathies (hypophysitis, thyroiditis, adrenal insufficiency). While full clinical management of these conditions is Step 2/3 material, recognizing the mechanism is fair game for Step 1.